Kennedy Capital Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.45M Buy
176,470
+12,733
+8% +$462K 0.12% 276
2026
Q2
$5.79M Buy
163,737
+41,840
+34% +$1.24M 0.1% 301
2026
Q1
$3.38M Buy
121,897
+10,002
+9% +$257K 0.07% 356
2025
Q4
$2.43M Buy
111,895
+2,324
+2% +$45.9K 0.05% 402
2025
Q3
$1.66M Buy
109,571
+53,869
+97% +$667K 0.04% 463
2025
Q2
$628K Buy
55,702
+2,109
+4% +$22.9K 0.02% 535
2025
Q1
$541K Buy
53,593
+685
+1% +$7.41K 0.01% 577
2024
Q4
$626K Buy
52,908
+9,801
+23% +$116K 0.01% 628
2024
Q3
$497K Buy
43,107
+6,194
+17% +$70.5K 0.01% 636
2024
Q2
$390K Buy
36,913
+10,717
+41% +$117K 0.01% 650
2024
Q1
$276K Buy
+26,196
New +$282K 0.01% 681

Other funds holding ROIV

Kennedy Capital Management's ROIV Position: Q3 2026 in Review

Kennedy Capital Management increased its Roivant Sciences (ROIV) stake by 7.8% in Q3 2026, buying an estimated $462K and bringing the position to 176,470 shares worth $6.45M. The position accounts for 0.12% of the portfolio, ranked #276.

Kennedy Capital Management first reported a position in ROIV in Q1 2024 and has held it in 11 quarters since. 522 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Kennedy Capital Management held 176,470 shares of Roivant Sciences worth $6.45M as of Q3 2026.
  • Kennedy Capital Management bought 12,733 Roivant Sciences shares in Q3 2026, an estimated $462K.
  • Roivant Sciences made up 0.12% of Kennedy Capital Management's portfolio in Q3 2026, its #276 holding.
  • Kennedy Capital Management first reported a position in Roivant Sciences in Q1 2024 and has held it in 11 quarters since.
  • 522 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.